Eslovênia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alvogen ipco s.ar.l - temozolomid - kapsula, trda - temozolomid 20 mg / 1 kapsula - temozolomid

Eslovênia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alvogen ipco s.ar.l - temozolomid - kapsula, trda - temozolomid 5 mg / 1 kapsula - temozolomid

Eslovênia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alvogen ipco s.ar.l - temozolomid - kapsula, trda - temozolomid 180 mg / 1 kapsula - temozolomid

Eslovênia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alvogen ipco s.ar.l - temozolomid - kapsula, trda - temozolomid 250 mg / 1 kapsula - temozolomid

Eslovênia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alvogen ipco s.ar.l - temozolomid - kapsula, trda - temozolomid 140 mg / 1 kapsula - temozolomid

União Europeia - esloveno - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). zdravilo olumiant se lahko uporablja kot monoterapija ali v kombinaciji z metotreksatom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

União Europeia - esloveno - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

União Europeia - esloveno - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopic - drugi dermatološki preparati - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

União Europeia - esloveno - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresivi - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Eslovênia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gedeon richter plc. - etinilestradiol; klormadinonacetat - filmsko obložena tableta - etinilestradiol 0,03 mg / 1 tableta  klormadinonacetat2 mg / 1 tableta; klormadinonacetat 2 mg / 1 tableta - klormadinon in etinilestradiol